Jazz Pharmaceuticals Plc · NASDAQ:JAZZ
Jazz Pharmaceuticals — 41st Annual J.P. Morgan Healthcare Conference (January 2023)
36 slides from Jazz Pharmaceuticals's conference presentation, Jan 9, 2023
Slide 1: 41st Annual J.P. Morgan Healthcare Conference
41st Annual J.P. Morgan Healthcare Conference Innovating to Transform the Lives of Patients and Their Families January 9, 2023 Grace Epidiolex patient Exhibit 99.1
Slide 2: Caution Concerning Forward-Looking Statements
Transforming Lives. Redefining Possibilities. Caution Concerning Forward-Looking Statements This presentation contains forward-looking statements and financial targets, including, but not limited to, statements related to: the Company’s growth prospects and future financial and operating results, in
Slide 3: Non-GAAP Financial Measures
Transforming Lives. Redefining Possibilities. Non-GAAP Financial Measures To supplement Jazz Pharmaceuticals’ financial results and guidance presented in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP (also referred to as adjusted or non-GAAP
Slide 4: Our Purpose / Who We Are
Our Purpose Who We Are is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases, often with limited or no therapeutic options, so they can live their lives more fully. By transforming biopharmaceutical
Slide 5: Jazz Has A Track Record of Strong Execution
Expect to meet 2022 total, neuroscience and oncology revenue guidance1 18% Revenue CAGR2 2017 – 2022 18 Consecutive Years YoY revenue growth 2005 – 2022 $3,094 Revenue $ in millions $3,600 - $3,7001 CAGR – compound annual growth rate, YoY = year-over- year. 1Guidance provided by Jazz Pharmaceuticals
Slide 6: Vision 2025 to Deliver Sustainable Growth and Enhanced Value
Vision 2025 to Deliver Sustainable Growth and Enhanced Value PIPELINE Delivering ≥5 novel product approvals by end of the decade Generating $5 billion in revenue in 2025 COMMERCIAL Driving 5%1 adjusted operating margin2 improvement from 20213 to 2025 OPERATIONAL EXCELLENCE Vision 2025 represents Jaz
Slide 7: Vision 2025 is Built on Our Core Strengths
Vision 2025 is Built on Our Core Strengths Vision 2025 represents Jazz estimates of future performance. 1Five percentage points; 2Adjusted operating margin is a non-GAAP financial measure. For further information, see “Non-GAAP Financial Measures”; 32021 adjusted operating margin calculation is incl
Slide 8: Strong 2022 Execution Positions Jazz Well to Achieve Vision 2025
Strong 2022 Execution Positions Jazz Well to Achieve Vision 2025 2L = second line, BTC = Biliary tract cancer; CAGR = compound annual growth rate; IH = idiopathic hypersomnia, IM = intramuscular; IND = Investigational New Drug Application, M/W/F = Monday, Wednesday, Friday, PDT = Parkinson’s disease
Slide 9: Strategic Transactions Drive Growth and Shareholder Value
Strategic Transactions Drive Growth and Shareholder Value OPERATIONAL EXCELLENCE Corporate Development Progress Contributes to Vision 2025 Transformational Transaction GW ACQUISITION Epidiolex blockbuster potential Combined company - leader in neuroscience Global commercial and operational footprint
Slide 10: Continuing to Rapidly Transform Revenue Base
Continuing to Rapidly Transform Revenue Base 1Guidance provided by Jazz Pharmaceuticals plc on and as of November 9, 2022. The company expects that, for the year ended December 31, 2022, reported total revenues will meet the guidance range provided on November 9, 2022. Jazz Pharmaceuticals plc has n
Slide 11: Vision 2025 Execution: Commercial
Vision 2025 Execution: Commercial Generating $5 Billion in Revenue in 2025 January 2023
Slide 12: Commercial Excellence Drives Growth
Commercial Excellence Drives Growth …POSITIONS JAZZ WELL TO DELIVER ON VISION 2025 TRACK RECORD OF SUCCESSFUL COMMERCIAL EXECUTION… Leading neuroscience franchises #1 treatment in narcolepsy & global cannabinoid franchises Blockbuster potential Durable oxybate franchise Executing successful Xywav La
Slide 13: Xywav Success Reinforces Durable Oxybate Franchise
Xywav Success Reinforces Durable Oxybate Franchise 1Vision 2025 represents Jazz estimates of future performance. FDA = Food & Drug Administration, IH = idiopathic hypersomnia, HCP = healthcare provider, REMS = Risk Evaluation and Mitigation Strategy, AGs = Authorized generics FOUNDATION OF OXYBATE S
Slide 14: Expansion into Idiopathic Hypersomnia Creates Growth Opportunity
Expansion into Idiopathic Hypersomnia Creates Growth Opportunity IH = idiopathic hypersomnia, FDA = Food and Drug Administration, MOA = mechanism of action Received Orphan Drug Exclusivity (ODE) in IH ~37,000 patients in the U.S. diagnosed & actively seeking healthcare Potential overall U.S. patient
Slide 15: Executing Successful Xywav Launches
Executing Successful Xywav Launches Xywav on track to be oxybate of choice in 2023 Vision 20252: ~$2 billion oxybate franchise Compelling Xywav adoption across both narcolepsy and IH continues to drive oxybate durability Growth driven by both adoption and new patient starts 1Approximate active Xywav
Slide 16: Epidiolex: High Unmet Need in Pediatric Onset Epilepsy
Epidiolex: High Unmet Need in Pediatric Onset Epilepsy FDA = Food & Drug Administration, LGS = Lennox-Gastaut syndrome, TSC = tuberous sclerosis complex The first and only FDA-approved prescription cannabidiol The only treatment indicated for seizures associated with TSC, LGS, and Dravet syndrome in
Slide 17: Epidiolex Revenue Growth Underscores Blockbuster Potential
Epidiolex Revenue Growth Underscores Blockbuster Potential Net product sales ($ in millions) 19% year-over-year growth in LTM to 3Q22 driven by underlying demand Market research indicates nearly 60% of providers are using Epidiolex earlier in their treatment algorithm Continue to add new prescribers
Slide 18: Rapidly Growing Oncology Business, Approaching $1B in Revenue
VISION 2025: >$1B1 2022G = Guidance provided by Jazz Pharmaceuticals plc on and as of November 9, 2022. 1Vision 2025 represents Jazz estimates of future performance. Rapidly Growing Oncology Business, Approaching $1B in Revenue COMMERCIAL PIPELINE OPERATIONAL EXCELLENCE Revenue $ in millions $860 -
Slide 19: Zepzelca: Rapidly Established as Treatment of Choice in 2L SCLC
Zepzelca: Rapidly Established as Treatment of Choice in 2L SCLC 1L = first-line, 2L = second-line, SCLC = small cell lung cancer. 1Net product sales from launch in July 2020 to September 30, 2022; 2F. Hoffmann-La Roche Ltd. PIPELINE COMMERCIAL PIPELINE OPERATIONAL EXCELLENCE Established as 2L Treatm
Slide 20: Rely on Rylaze: Successful Launch and Strong Demand
Rely on Rylaze: Successful Launch and Strong Demand ALL/LBL = acute lymphoblastic leukemia / lymphoblastic lymphoma, EMA = European Medicines Agency, HCP = healthcare providers, IM = intramuscular, IV = intravenous, M/W/F = Monday, Wednesday, Friday, MAA = Marketing Authorisation Application, RTOR =
Slide 21: Vision 2025 Execution: Pipeline
Vision 2025 Execution: Pipeline Expanded Capabilities Driving Future Growth Potential January 2023
Slide 22: Highly Productive R&D Engine Drives Value
Highly Productive R&D Engine Drives Value …POSITIONS JAZZ WELL TO DELIVER ON VISION 2025 TRACK RECORD OF SUCCESS, STRONG EXECUTION AND EXPANDED CAPABILITIES… COMMERCIAL PIPELINE OPERATIONAL EXCELLENCE Product approvals and launches in 2020–2021 Total pipeline projects Expanded >4x since 2015 Product
Slide 23: Expanded R&D Capabilities Provide Expertise and Scale
Expanded R&D Capabilities Provide Expertise and Scale COMMERCIAL PIPELINE OPERATIONAL EXCELLENCE Expanded In-house end-to-end drug development capabilities Enhanced medicinal chemistry & translational biology capabilities Differentiated capabilities in cannabinoids and nanoparticle drug delivery BRE
Slide 24: Near-term R&D Pipeline Opportunities
PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 PHASE 4 / Regulatory KEY CATALYSTS Epidiolex Phase 3 Initiated Fourth target indication Phase 3 First Patient Enrolled JZP150 Phase 2 Top-line Data Readout Expected late 2023 Suvecaltamide (JZP385) Phase 2b Top-line Data Readout Expected 1H24 Phase 2 Initiated JZ
Slide 25: Vision 2025 Execution: Operational Excellence
Vision 2025 Execution: Operational Excellence Financial Strength and Discipline Enables Future Growth January 2023
Slide 26: Delivering Significant Value Through Strategic Capital Allocation
Delivering Significant Value Through Strategic Capital Allocation 1As of September 30, 2022. COMMERCIAL PIPELINE OPERATIONAL EXCELLENCE CAPITAL DISCIPLINED DEPLOYMENT STRATEGIC PRIORITIES COMMERCIAL GROWTH New indications Geographic expansion PIPELINE EXPANSION Advancing internal assets Licensing ne
Slide 27: Jazz Has Consistently Delivered Top- and Bottom-Line Growth
Jazz Has Consistently Delivered Top- and Bottom-Line Growth REVENUE GROWTH GUIDED BY OUR PATIENT-CENTRIC APPROACH 2017 – 2022: 18% Revenue CAGR2 2005 – 2022: YoY revenue growth for 18 Consecutive years $3,094 Revenue $ in millions $3,600 - $3,7001 operational excellence and operating margin improvem
Slide 28: First ESG Report Published
First ESG Report Published *The 2021 ESG report is available on the Investors section of www.jazzpharmaceuticals.com and is based on data for the calendar year 2021. DEIB = diversity, equity, inclusion and belonging, ERTs = employee resource teams, ESG = environmental, social and governance, R&D = r
Slide 29: Delivering Sustainable Growth and Shareholder Value
Delivering Sustainable Growth and Shareholder Value COMMERCIAL OPERATIONAL EXCELLENCE Transforming Lives. Redefining Possibilities. COMMERCIAL PIPELINE OPERATIONAL EXCELLENCE Patient-centric innovation drives our strategy 2022 execution positions us well to achieve Vision 2025 Strong financial found
Slide 30: Thank You
Thank You O= Pharmaceuticals.
Slide 31: Appendix
Appendix @ Jazz Pharmaceuticals.
Slide 32: 1Partnered collaboration; 2Recently acquired; 3Planned; 4Jazz & MD Anderson Cancer Center collaboration study; 5JZP150
1Partnered collaboration; 2Recently acquired; 3Planned; 4Jazz & MD Anderson Cancer Center collaboration study; 5JZP150 is a fatty acid amide hydrolase inhibitor which modulates the endocannabinoid anandamide; 6HERIZON-BTC-01; 7Cooperative group study; 8HERIZON-GEA-01; 9FDA approval on June 30, 2021
Slide 33: Non-GAAP Adjusted Operating Margin – Year Ended December 31, 2021
In millions, except % (unaudited) Year ended December 31, 2021 Revenue $3,094 Adjusted cost of product sales, SG&A and R&D expenses $1,761 Non-GAAP adjusted operating margin 43% In millions (unaudited) Cost of product sales SG&A R&D Total GAAP reported $441 $1,452 $506 $2,398 Share-based compensatio
Slide 34: Non-GAAP Adjusted Operating Margin – FY 2022 Guidance
In millions, except % (unaudited) FY 2022 G Revenue $3,650 Adjusted cost of product sales, SG&A and R&D expenses $1,866 Non-GAAP adjusted operating margin 49% In millions (unaudited) Cost of product sales G SG&A G R&D G Total G GAAP $541 $1,360 $578 $2,479 Share-based compensation (12) (140) (59) (2
Slide 35: Pro Forma Non-GAAP Net Leverage Ratio
Pro Forma Non-GAAP Net Leverage Ratio Reconciliation of Pro Forma GAAP Net income to Pro Forma Non-GAAP Adjusted EBITDA1 (calculated in accordance with the Company’s Credit Agreement) and the Calculation of Pro Forma Non-GAAP Net Leverage Ratio In millions (unaudited) LTM Ended 09/30/22 LTM Ended 03
Slide 36: Explanation of Adjustments and Certain Line Items
Explanation of Adjustments and Certain Line Items: Transaction and integration expenses in 2021 related to the GW Acquisition and in 2016 related to the Celator Acquisition. Non-cash interest expense associated with debt discount and debt issuance costs. Expense arising on the remeasurement of the C
Jazz Pharmaceuticals — 41st Annual J.P. Morgan Healthcare Conference (January 2023) on 6ix